CardioSomaticsCardioSomaticsCardioСоматика2221-71852658-5707Eco-Vector62650310.17816/CS626503ReviewsОбзорыResearch ArticleCOVID-19 and post-disease features in patients with obesityОсобенности течения COVID-19 и постковидного периода у пациентов с ожирениемhttps://orcid.org/0009-0004-9513-32244452-9439FrolovaEkaterina S.ФроловаЕкатерина Станиславовна
Russian Federation
frolovaec@mail.ruhttps://orcid.org/0000-0002-5610-4314VeselovskyPavel P.ВеселовскийПавел Петрович
Russian Federation
veselovskiipasha@mail.ruhttps://orcid.org/0000-0002-2810-65318292-9080ChumakovaGalina A.ЧумаковаГалина Александровна
Russian Federation

MD, Dr. Sci. (Medicine), Professor

доктор мед. наук, профессор

g.a.chumakova@mail.ruhttps://orcid.org/0000-0001-8654-70204213-4686VeselovskayaNadezhda G.ВеселовскаяНадежда Григорьевна
Russian Federation

MD, Dr. Sci. (Medicine), Professor

доктор мед. наук, профессор

nadezhda100@rambler.ruhttps://orcid.org/0000-0002-7248-98677131-7519OttAnna V.ОттАнна Владимировна
Russian Federation

Cand. Sci. (Medicine), assistant

кандидат мед. наук, ассистент

ott-88@mail.ruAltai Regional Cardiology DispensaryАлтайский краевой кардиологический диспансерAltai State Medical UniversityАлтайский государственный медицинский университет04122024251220241543443530602202426112024Copyright ©; 2024, Eco-VectorCopyright ©; 2024, ООО "Эко-Вектор"2024Eco-VectorООО "Эко-Вектор"https://creativecommons.org/licenses/by-nc-nd/4.0https://cardiosomatics.ru/2221-7185/article/view/626503

The COVID-19 pandemic has affected the global population, causing significant economic effect, material damage, and irreparable human losses. Many countries were forced to promptly reorganize their healthcare system in order to save patients with COVID-19. The pathogenesis and specifics of the disease are not completely understood, but one pattern is particularly clear: COVID-19 tends to be more severe in people with obesity. Fatty tissue is known to support chronic low-grade inflammation and has its own endocrine activity. Over time, it became obvious that some patients still have consequences following the acute phase of COVID-19, which in some cases lead to irreversible changes in the body and reduced quality of life. This condition was called post-COVID syndrome. In this article, we review the long-term effects of COVID-19 on different body systems. We focused on pathogenic infection mechanisms and features of post-COVID syndrome in people with obesity.

Пандемия COVID-19 затронула население всей планеты, нанеся значительный экономический и материальный ущерб и непоправимые человеческие потери. Многие страны были вынуждены оперативно перестроить систему здравоохранения для спасения пациентов с COVID-19. Патогенез и особенности течения данного заболевания изучены не до конца, однако одна закономерность прослеживается особенно отчётливо: люди, страдающие ожирением, переносят COVID-19 значительно тяжелее. Как известно, жировая ткань обладает свойством поддерживать хроническое низкоинтенсивное воспаление, а также имеет свою эндокринную активность. С течением времени стало очевидно, что у части пациентов после завершения острой фазы COVID-19 остаются последствия, которые в ряде случаев приводят к необратимым изменениям в организме и снижению качества жизни. Это состояние получило название «постковидный синдром». В данном обзоре мы рассматриваем влияние COVID-19 на разные системы органов в отдалённом периоде. Большое внимание уделяем патогенетическим механизмам течения инфекции и особенностям постковидного синдрома у пациентов с ожирением.

obesityCOVID-19post-COVID syndromepathogenic mechanismsожирениеCOVID-19постковидный синдромпатогенетические механизмыOchani R, Asad A, Yasmin F, et al. COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management. Infez Med. 2021;29(1):20–36.Ochani R., Asad A., Yasmin F., et al. COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management // Infez Med. 2021. Vol. 29, N 1. P. 20–36.Han Q, Zheng B, Daines L, Sheikh A. Long-Term Sequelae of COVID-19: A Systematic Review and Meta-Analysis of One-Year Follow-Up Studies on Post-COVID Symptoms. Pathogens. 2022;11(2):269. doi: 10.3390/pathogens11020269Han Q., Zheng B., Daines L., Sheikh A. Long-Term Sequelae of COVID-19: A Systematic Review and Meta-Analysis of One-Year Follow-Up Studies on Post-COVID Symptoms // Pathogens. 2022. Vol. 11, N 2. P. 269. doi: 10.3390/pathogens11020269Liu E, Lee H, Lui B, et al. Respiratory and nonrespiratory COVID-19 complications in patients with obesity: recent developments. J Comp Eff Res. 2022;11(5):371–381. doi: 10.2217/cer-2021-0237Liu E., Lee H., Lui B., et al. Respiratory and nonrespiratory COVID-19 complications in patients with obesity: recent developments // J Comp Eff Res. 2022. Vol. 11, N 5. P. 371–381. doi: 10.2217/cer-2021-0237World Health Organization. World leaders express strong support for WHO at G20. Available from: https://www.who.int/homeWorld Health Organization. World leaders express strong support for WHO at G20. Режим доступа: https://www.who.int/home. Дата обращения: 04.08.2024 г.Federal State Statistics Service. Available from: https://rosstat.gov.ruФедеральная служба государственной статистики. Режим доступа: https://rosstat.gov.ru. Дата обращения: 30.09.2024 г.Leskova IV, Ershova EV, Nikitina EA, et al. Obesity in Russia: modern view in the light of a social problems. Obesity and metabolism. 2019;16(1):20–26. EDN: KDEROH doi: 10.14341/omet9988Лескова И.В., Ершова Е.В., Никитина Е.А., и др. Ожирение в России: современный взгляд под углом социальных проблем // Ожирение и метаболизм. 2019. Т. 16, № 1. С. 20–26. EDN: KDEROH doi: 10.14341/omet9988Kravchuk EN, Neimark AE, Babenko AYu, et al. Obesity and COVID-19. Arterial Hypertension. 2020;26(4):440–446. EDN: IFIREM doi: 10.18705/1607-419X-2020-26-4-440-446Кравчук Е.Н., Неймарк А.Е., Бабенко А.Ю., и др. Ожирение и COVID-19 // Артериальная гипертензия. 2020. Т. 26, № 4. С. 440446. EDN: IFIREM doi: 10.18705/1607-419X-2020-26-4-440-446Razina AО, Runenko SD, Achkasov EЕ. Obesity: Current Global and Russian Trends. Annals of the Russian Academy of Medical Sciences. 2016;71(2):154–159. EDN: VYQBYN doi: 10.15690/vramn655Разина А.О., Руненко С.Д., Ачкасов Е.Е. Проблема ожирения: современные тенденции в России и в мире // Вестник РАМН. 2016. Т. 71, № 2. С. 154–159. EDN: VYQBYN doi: 10.15690/vramn655Gammone M, D’Orazio N. COVID-19 and Obesity: Overlapping of Two Pandemics. Obes Facts. 2021;14(6):579–585. doi: 10.1159/000518386Gammone M.A., D’Orazio N. COVID-19 and Obesity: Overlapping of Two Pandemics // Obes Facts. 2021. Vol. 14, N 6. P. 579–585. doi: 10.1159/000518386Baklaushev VP, Kulemzin SV, Gorchakov АА, et al. COVID-19. Etiology, Pathogenesis, Diagnosis and Treatment. Journal of Clinical Practice. 2020;11(1):7–20. EDN: COJLTB doi: 10.17816/clinpract26339Баклаушев В.П., Кулемзин С.В., Горчаков А.А., и др. COVID-19. Этиология, патогенез, диагностика и лечение // Клиническая практика. 2020. Т. 11, № 1. С. 7–20. EDN: COJLTB doi: 10.17816/clinpract26339Nikiforov VV, Suranova TG, Chernobrovkina TYa, et al. New Coronavirus Infection (COVID-19): Clinical and Epidemiological Aspects. The Russian Archives of Internal Medicine. 2020;10(2):87–93. EDN: MELBOP doi: 10.20514/2226-6704-2020-10-2-87-93Никифоров В.В., Суранова Т.Г., Чернобровкина Т.Я., и др. Новая коронавирусная инфекция (COVID-19): клинико-эпидемиологические аспекты // Архивъ внутренней медицины. 2020. Т. 10, № 2. С. 87–93. EDN: MELBOP doi: 10.20514/2226-6704-2020-10-2-87-93Shatunova PO, Bykov AS, Svitich OA, Zverev VV. Angiotensin-converting enzyme 2. Approaches to pathogenetic therapy of COVID-19. Journal of microbiology, epidemiology and immunobiology. 2020;97(4):339–345. EDN: PMHTVH doi: 10.36233/0372-9311-2020-97-4-6Шатунова П.О., Быков А.С., Свитич О.А., Зверев В.В. Ангиотензинпревращающий фермент 2. Подходы к патогенетической терапии COVID-19 // Журнал микробиологии, эпидемиологии и иммунобиологии. 2020. Т. 97, № 4. С. 339–345. EDN: PMHTVH doi: 10.36233/0372-9311-2020-97-4-6Hoffmann M, Kleine-Weber H, Krüger N, et al. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. BioRxiv. 2020. doi: 10.1101/2020.01.31.929042Hoffmann M., Kleine-Weber H., Krüger N., et al. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells // BioRxiv. 2020. doi: 10.1101/2020.01.31.929042Carluccio M, Soccio M, De Caterina R. Aspects of gene polymorphisms in cardiovascular disease: the renin-angiotensin system. Eur J Clin Invest. 2001;31(6):476–488. doi: 10.1046/j.1365-2362.2001.00839.xCarluccio M., Soccio M., De Caterina R. Aspects of gene polymorphisms in cardiovascular disease: the renin-angiotensin system // Eur J Clin Invest. 2001. Vol. 31, N 6. P. 476–488. doi: 10.1046/j.1365-2362.2001.00839.xMehta P, McAuley DF, Brown M, et al. HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034. doi: 10.1016/S0140-6736(20)30628-0Mehta P., McAuley D., Brown M., et al. HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression // Lancet. 2020. Vol. 395, N 10229. P. 1033–1034. doi: 10.1016/S0140-6736(20)30628-0Welch WJ. Angiotensin II-dependent superoxide: effects on hypertension and vascular dysfunction. Hypertension. 2008;52(1):51–56. doi: 10.1161/HYPERTENSIONAHA.107.090472Welch W. Angiotensin II-dependent superoxide: effects on hypertension and vascular dysfunction // Hypertension. 2008. Vol. 52, N 1. P. 51–56. doi: 10.1161/HYPERTENSIONAHA.107.090472Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529–539. doi: 10.1007/s00281-017-0629-xChannappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology // Semin Immunopathol. 2017. Vol. 39, N 5. P. 529–539. doi: 10.1007/s00281-017-0629-xCaussy C, Pattou F, Wallet F, et al. Prevalence of obesity among adult inpatients with COVID-19 in France. Lancet Diabetes Endocrinol. 2020;8(7):562–564. doi: 10.1016/S2213-8587(20)30160-1Caussy C., Pattou F., Wallet F., et al. Prevalence of obesity among adult inpatients with COVID-19 in France // Lancet Diabetes Endocrinol. 2020. Vol. 8, N 7. P. 562–564. doi: 10.1016/S2213-8587(20)30160-1Vanhems, Philippe et al. Factors associated with admission to intensive care units in COVID-19 patients in Lyon-France. PloS One. 2021;16(1):e0243709. doi: 10.1371/journal.pone.0243709Vanhems P., Gustin M., Elias C., et al. Factors associated with admission to intensive care units in COVID-19 patients in Lyon-France // PloS One. 2021. Vol. 16, N 1. P. e0243709. doi: 10.1371/journal.pone.0243709O’Hearn M, Liu J, Cudhea F, et al. Coronavirus Disease 2019 Hospitalizations Attributable to Cardiometabolic Conditions in the United States: A Comparative Risk Assessment Analysis. J Am Heart Assoc. 2021;10(5):e019259. doi: 10.1161/JAHA.120.019259O’Hearn M., Liu J., Cudhea F., et al. Coronavirus Disease 2019 Hospitalizations Attributable to Cardiometabolic Conditions in the United States: A Comparative Risk Assessment Analysis // J Am Heart Assoc. 2021. Vol. 10, N 5. P. e019259. doi: 10.1161/JAHA.120.019259Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966. doi: 10.1136/bmj.m1966Petrilli C., Jones S., Yang J., et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study // BMJ. 2020. Vol. 369. P. m1966. doi: 10.1136/bmj.m1966Cai Q, Chen F, Wang T, et al. Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China. Diabetes Care. 2020;43(7):1392–1398. doi: 10.2337/dc20-0576Cai Q., Chen F., Wang T., et al. Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China // Diabetes Care. 2020. Vol. 43(7):1392–1398. doi: 10.2337/dc20-0576Jia X., Yin C, Lu S, et al. Two Things about COVID-19 Might Need Attention. Preprint. 2020:2020020315. doi: 10.20944/preprints202002.0315.v1Jia X., Yin C., Lu S., et al. Two Things about COVID-19 Might Need Attention // Preprints. 2020. P. 2020020315. doi: 10.20944/preprints202002.0315.v1Stefan N, Birkenfeld AL, Schulze MB. Global pandemics interconnected — obesity, impaired metabolic health and COVID-19. Nat Rev Endocrinol. 2021;17(3):135–149. doi: 10.1038/s41574-020-00462-1Stefan N., Birkenfeld A., Schulze M. Global pandemics interconnected — obesity, impaired metabolic health and COVID-19 // Nat Rev Endocrinol. 2021. Vol. 17, N 3. P. 135–149. doi: 10.1038/s41574-020-00462-1Yan T, Xiao R, Lin G. Angiotensin-converting enzyme 2 in severe acute respiratory syndrome coronaviruse and SARS-CoV-2: A double-edged sword? FASEB J. 2020;34:6017–6026. doi: 10.1096/fj.202000782Yan T., Xiao R., Lin G. Angiotensin-converting enzyme 2 in severe acute respiratory syndrome coronaviruse and SARS-CoV-2: A double-edged sword? // FASEB J. 2020. Vol. 34, N 5. P. 6017–6026. doi: 10.1096/fj.202000782Bandaru P, Rajkumar H, Nappanveettil G. The Impact of Obesity on Immune Response to Infection and Vaccine: An Insight into Plausible Mechanisms. Endocrinol Metab Synd. 2013;2:1000113. doi: 10.4172/2161-1017.1000113Bandaru P., Rajkumar H., Nappanveettil G. The Impact of Obesity on Immune Response to Infection and Vaccine: An Insight into Plausible Mechanisms // Endocrinol Metab Synd. 2013. Vol. 2. P. 1000113. doi: 10.4172/2161-1017.1000113Muscogiuri G, Pugliese G, Laudisio D, et al. The impact of obesity on immune response to infection: Plausible mechanisms and outcomes. Obes Rev. 2021;22(6):e13216. doi: 10.1111/obr.13216Muscogiuri G., Pugliese G., Laudisio D., et al. The impact of obesity on immune response to infection: Plausible mechanisms and outcomes // Obes Rev. 2021. Vol. 22, N 6. P. e13216. doi: 10.1111/obr.13216Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19. J Infect. 2020;80(6):607–613. doi: 10.1016/j.jinf.2020.03.037Ye Q., Wang B., Mao J. The pathogenesis and treatment of the "Cytokine Storm" in COVID-19 // J Infect. 2020. Vol. 80, N 6. P. 607–613. doi: 10.1016/j.jinf.2020.03.037Mirsoian A, Bouchlaka MN, Sckisel GD, et al. Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice. J Exp Med. 2014;211(12):2373–2383. doi: 10.1084/jem.20140116Mirsoian A., Bouchlaka M., Sckisel G., et al. Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice. J Exp Med. 2014. Vol. 211, N 12. P. 2373–2783. doi: 10.1084/jem.20140116De Leeuw A, Oude Luttikhuis M, Wellen A, et al. Obesity and its impact on COVID-19. J Mol Med (Berl). 2021;99(7):899–915. doi: 10.1007/s00109-021-02072-4De Leeuw A., Oude Luttikhuis M, Wellen A, et al. Obesity and its impact on COVID-19 // J Mol Med (Berl). 2021. Vol. 99, N 7. P. 899–915. doi: 10.1007/s00109-021-02072-4Muskiet FAJ, Carrera-Bastos P, Pruimboom L, et al. Obesity and leptin resistance in the regulation of the type I interferon early response and the increased risk for severe COVID-19. Nutrients. 2022;14(7):1388. doi: 10.3390/nu14071388Muskiet F., Carrera-Bastos P., Pruimboom L., et al. Obesity and leptin resistance in the regulation of the type I interferon early response and the increased risk for severe COVID-19 // Nutrients. 2022. Vol. 14, N 7. P. 1388. doi: 10.3390/nu14071388Zhou Y, Rui L. Leptin signaling and leptin resistance. Front Med. 2013;7(2):207–222. doi: 10.1007/s11684-013-0263-5Zhou Y., Rui L. Leptin signaling and leptin resistance // Front Med. 2013. Vol. 7, N 2. P. 207–222. doi: 10.1007/s11684-013-0263-5Van der Voort P, Moser J, Zandstra D, et al. Leptin levels in SARS-CoV-2 infection related respiratory failure: A cross-sectional study and a pathophysiological framework on the role of fat tissue. Heliyon. 2020;6(8):e04696. doi: 10.1016/j.heliyon.2020.e04696Van der Voort P., Moser J., Zandstra D., et al. Leptin levels in SARS-CoV-2 infection related respiratory failure: A cross-sectional study and a pathophysiological framework on the role of fat tissue // Heliyon. 2020. Vol. 6, N 8. P. e04696. doi: 10.1016/j.heliyon.2020.e04696Maier H, Lopez R, Sanchez N, et al. Obesity Increases the Duration of Influenza A Virus Shedding in Adults. J Infect Dis. 2018;218(9):1378–1382. doi: 10.1093/infdis/jiy370Maier H., Lopez R., Sanchez N., et al. Obesity Increases the Duration of Influenza A Virus Shedding in Adults // J Infect Dis. 2018. Vol. 218, N 9. P. 1378–1382. doi: 10.1093/infdis/jiy370Lasbleiz A, Gaborit B, Soghomonian A, et al. COVID-19 and Obesity: Role of Ectopic Visceral and Epicardial Adipose Tissues in Myocardial Injury. Front Endocrinol (Lausanne). 2021;12:726967. doi: 10.3389/fendo.2021.726967Lasbleiz A., Gaborit B., Soghomonian A., et al. COVID-19 and Obesity: Role of Ectopic Visceral and Epicardial Adipose Tissues in Myocardial Injury // Front Endocrinol (Lausanne). 2021. Vol. 12. P. 726967. doi: 10.3389/fendo.2021.726967Bihan H, Heidar R, Beloeuvre A, et al. Epicardial adipose tissue and severe Coronavirus Disease 19. Cardiovasc Diabetol. 2021;20(1):147. doi: 10.1186/s12933-021-01329-zBihan H., Heidar R., Beloeuvre A., et al. Epicardial adipose tissue and severe Coronavirus Disease 19 // Cardiovasc Diabetol. 2021. Vol. 20, N 1. P. 147. doi: 10.1186/s12933-021-01329-zPasquarelli-do-Nascimento G, Braz-de-Melo H, Faria S, et al. Hypercoagulopathy and adipose tissue exacerbated inflammation may explain higher mortality in COVID-19 patients with obesity. Front Endocrinol (Lausanne). 2020;11:530. doi: 10.3389/fendo.2020.00530Pasquarelli-do-Nascimento G., Braz-de-Melo H., Faria S., et al. Hypercoagulopathy and adipose tissue exacerbated inflammation may explain higher mortality in COVID-19 patients with obesity // Front Endocrinol (Lausanne). 2020. Vol. 28, N 11. P. 530. doi: 10.3389/fendo.2020.00530Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020;18(7):1738–1742. doi: 10.1111/jth.14850Panigada M., Bottino N., Tagliabue P., et al. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis // J Thromb Haemost. 2020. Vol. 18, N 7. P. 1738–1742. doi: 10.1111/jth.14850Rubin R. As Their Numbers Grow, COVID-19 ”Long Haulers” Stump Experts. JAMA. 2020;324(14):1381–1383. doi:10.1001/jama.2020.17709Rubin R. As Their Numbers Grow, COVID-19 ”Long Haulers” Stump Experts // JAMA. 2020. Vol. 324, N 14. P. 1381–1383. doi:10.1001/jama.2020.17709Van der Meijden PEJ, Heemskerk JWM. Platelet biology and functions: new concepts and clinical perspectives. Nat Rev Cardiol. 2019;16(3):166–179. doi: 10.1038/s41569-018-0110-0Van der Meijden P., Heemskerk J. Platelet biology and functions: new concepts and clinical perspectives // Nat Rev Cardiol. 2019. Vol. 16, N 3. P. 166–179. doi: 10.1038/s41569-018-0110-0Lechner-Scott J, Levy M, Hawkes C, et al. Long COVID or post COVID-19 syndrome. Mult Scler Relat Disord. 2021;55:103268. doi: 10.1016/j.msard.2021.103268Lechner-Scott J., Levy M., Hawkes C., et al. Long COVID or post COVID-19 syndrome // Mult Scler Relat Disord. 2021. Vol. 55. P. 103268. doi: 10.1016/j.msard.2021.103268Raman B, Bluemke DA, Lüscher TF, Neubauer S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. Eur Heart J. 2022;43(11):1157–1172. doi: 10.1093/eurheartj/ehac031Raman B., Bluemke D., Lüscher T., Neubauer S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus // Eur Heart J. 2022. Vol. 43, N 11. P. 1157–1172. doi: 10.1093/eurheartj/ehac031COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: National Institute for Health and Care Excellence (NICE); 2020.COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: National Institute for Health and Care Excellence (NICE). 2024.Scholkmann F, May CA. COVID-19, post-acute COVID-19 syndrome (PACS, ”long COVID”) and post-COVID-19 vaccination syndrome (PCVS, ”post-COVIDvac-syndrome”): Similarities and differences. Pathol Res Pract. 2023;246:154497. doi: 10.1016/j.prp.2023.154497Scholkmann F., May C. COVID-19, post-acute COVID-19 syndrome (PACS, ”long COVID”) and post-COVID-19 vaccination syndrome (PCVS, ”post-COVIDvac-syndrome”): Similarities and differences // Pathol Res Pract. 2023. Vol. 246. P. 154497. doi: 10.1016/j.prp.2023.154497Chopra V, Flanders SA, O’Malley M, et al. Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med. 2021;174(4):576–578. doi: 10.7326/M20-5661Chopra V., Flanders S.A., O’Malley M., et al. Sixty-day outcomes among patients hospitalized with COVID-19 // Ann Intern Med. 2021. Vol. 174, N 4. P. 576-578. doi: 10.7326/M20-5661Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133–146. doi: 10.1038/s41579-022-00846-2Davis H., McCorkell L., Vogel J., Topol E. Long COVID: major findings, mechanisms and recommendations // Nat Rev Microbiol. 2023. Vol. 21, N 3. P. 133–146. doi: 10.1038/s41579-022-00846-2Kingstone T, Taylor AK, O’Donnell CA, et al. Finding the "right" GP: a qualitative study of the experiences of people with long-COVID. BJGP Open. 2020;4(5):bjgpopen20X101143. doi: 10.3399/bjgpopen20X101143Kingstone T., Taylor A., O’Donnell C., et al. Finding the ”right” GP: a qualitative study of the experiences of people with long-COVID // BJGP Open. 2020. Vol. 4, N 5. P. bjgpopen20X101143. doi: 10.3399/bjgpopen20X101143Naeije R, Caravita S. Phenotyping long COVID. Eur Respir J. 2021;58(2):2101763. doi: 10.1183/13993003.01763-2021Naeije R., Caravita S. Phenotyping long COVID // Eur Respir J. 2021. Vol. 58, N 2. P. 2101763. doi: 10.1183/13993003.01763-2021Dixit NM, Churchill A, Nsair A, Hsu JJ. Post-Acute COVID-19 Syndrome and the cardiovascular system: What is known? Am Heart J Plus. 2021;5:100025. doi: 10.1016/j.ahjo.2021.100025Dixit N., Churchill A., Nsair A., Hsu J. Post-Acute COVID-19 Syndrome and the cardiovascular system: What is known? // Am Heart J Plus. 2021. Vol. 5. P. 100025. doi: 10.1016/j.ahjo.2021.100025Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601–615. doi: 10.1038/s41591-021-01283-zNalbandian A., Sehgal K., Gupta A., et al. Post-acute COVID-19 syndrome // Nat Med. 2021. Vol. 27, N 4. P. 601–615. doi: 10.1038/s41591-021-01283-zOikonomou E, Souvaliotis N, Lampsas S, et al. Endothelial dysfunction in acute and long standing COVID-19: A prospective cohort study. Vascul Pharmacol. 2022;144:106975. doi: 10.1016/j.vph.2022.106975Oikonomou E., Souvaliotis N., Lampsas S., et al. Endothelial dysfunction in acute and long standing COVID-19: A prospective cohort study // Vascul Pharmacol. 2022. Vol. 144. P. 106975. doi: 10.1016/j.vph.2022.106975Sathish T, Tapp RJ, Cooper ME, et al. Potential metabolic and inflammatory pathways between COVID-19 and new-onset diabetes. Diabetes Metab. 2021;47(2):101204. doi: 10.1016/j.diabet.2020.10.002Sathish T., Tapp R., Cooper M., Zimmet P. Potential metabolic and inflammatory pathways between COVID-19 and new-onset diabetes // Diabetes Metab. 2021. Vol. 47, N 2. P. 101204. doi: 10.1016/j.diabet.2020.10.002